Alamar Biosciences (ALMR) Stock Overview
A proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ALMR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alamar Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.94 |
| 52 Week High | US$27.20 |
| 52 Week Low | US$18.85 |
| Beta | 0 |
| 1 Month Change | -11.87% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALMR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 9.5% | 6.5% | 0.3% |
| 1Y | n/a | 11.9% | 26.2% |
Return vs Industry: Insufficient data to determine how ALMR performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how ALMR performed against the US Market.
Price Volatility
| ALMR volatility | |
|---|---|
| ALMR Average Weekly Movement | 9.0% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALMR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ALMR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 222 | Yuling Luo | alamarbio.com |
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics.
Alamar Biosciences, Inc. Fundamentals Summary
| ALMR fundamental statistics | |
|---|---|
| Market cap | US$1.44b |
| Earnings (TTM) | -US$43.48m |
| Revenue (TTM) | US$87.16m |
Is ALMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMR income statement (TTM) | |
|---|---|
| Revenue | US$87.16m |
| Cost of Revenue | US$37.38m |
| Gross Profit | US$49.77m |
| Other Expenses | US$93.26m |
| Earnings | -US$43.48m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 57.11% |
| Net Profit Margin | -49.89% |
| Debt/Equity Ratio | 131.7% |
How did ALMR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 09:07 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alamar Biosciences, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Casey Woodring | J.P. Morgan |
| Puneet Souda | Leerink Partners LLC |